SUMM Summit Therapeutics Plc

Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that Mr Erik Ostrowski, CFO of Summit, will present a corporate overview at the Canaccord Genuity Growth Conference on 9 August 2017 at 10:30am EDT in Boston, Massachusetts, US.

A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

-END-

For more information, please contact: 

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455

Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson Tel: +44 (0)20 7213 0880

N+1 Singer 
(Broker)
Aubrey Powell / Lauren Kettle   Tel: +44 (0)20 7496 3000

MacDougall Biomedical Communications
(US media contact) Tel: +1 781 235 3060
Karen Sharma ksharma@macbiocom.com 

Consilium Strategic Communications
(Financial public relations, UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / summit@consilium-comms.com 
Jessica Hodgson / Lindsey Neville